# idiopathic pulmonary fibrosis (IPF) - deepseek-v4-flash

- Benchmark system: raw
- Repeat: 1
- Task type: PROGNOSIS
- Tissue / sample source: lung tissue
- Comparison or endpoint: all-cause mortality
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: d9fe74e971569d03f1ace047ce334e08d788b93d2057913b4d42b34da6d57d2f
- Response HTTP status: 200
- Prompt tokens: 3867
- Completion tokens: 25976
- Reasoning tokens: 
- Total tokens: 29843
- API requests reported: 
- Elapsed seconds: 280.025
- Final benchmark system: raw; file rank 1/5; original repeat 1; model vendor: DeepSeek

---
## Important data-quality note

Before biological interpretation, several rows in the supplied table should be set aside:

- `MIR221`, `IHH`, `HCN4`, `FAM75A2`, `OR2M2`, `XLOC_003303`, `DYDC2`, `DKFZP434L187`, and the `CONTROL_A_33_*` probes have HR values of ~10⁻²² or ~10²¹ with P = 0 / FDR = 0. These are almost certainly **statistical artifacts** from quasi-complete separation or near-zero variance in a Cox model, not interpretable biological hazard or protective effects. Several are reciprocal HR values, which is a classic sign of model non-identifiability.
- `LOC100128226` is the only finite protective signal (HR ≈ 0.007), but it is uncharacterized. There is insufficient annotation and mechanistic context to build a biological interpretation around it.

The following interpretation therefore focuses on the large block of well-behaved, FDR-significant risk-associated genes, nearly all with HR > 2.

---

## 1. Overall biological interpretation

Within IPF lung tissue, the prognostic transcriptome is overwhelmingly dominated by genes whose **higher expression is associated with increased all-cause mortality**. The overall pattern is not random: it points to a coordinated, advanced-injury biology involving:

- **Myeloid inflammation**, including both profibrotic macrophage programs and neutrophilic infiltration;
- **Aberrant epithelial differentiation**, including mucinous, squamous, and alveolar epithelial metaplasia;
- **Active growth factor / receptor tyrosine kinase signaling**, with direct ligand–receptor pairs such as HGF/MET;
- **Extracellular matrix remodeling** and matricellular signaling;
- **Oxidative stress, metal handling, and metabolic adaptation**, including the ferroptosis-related gene SLC7A11.

This expression profile is consistent with the histology of progressive IPF: fibrotic alveolar remodeling, hyperplastic or metaplastic epithelium, macrophage-rich inflammatory infiltrates, neutrophil activity, and a matrix that is continuously being deposited and degraded. Importantly, because the input is **prognostic within IPF**, not a case–control differential expression analysis, these genes are associated with survival once IPF is established; they are not necessarily genes that simply distinguish IPF from normal lung.

There is no credible protective biological program in this table. The protective signal is concentrated in one unannotated transcript, which is insufficient to define a protective pathway.

---

## 2. Core biological programs

### Program 1 — Myeloid inflammation and profibrotic macrophage / neutrophil activation

- **Direction:** Higher expression → increased mortality  
- **Representative genes:** `MERTK` HR 3.70, `SPP1` HR 3.40, `STAB1` HR 3.29, `CCL7` HR 3.02, `CXCL1` HR 2.99, `CXCR1` HR 3.28, `S100A12` HR 2.53, `SELL` HR 2.37, `CD177` HR 2.72, `MMP25` HR 3.26, `PROK2` HR 3.65  
- **Pathway anchor:** Hallmark Inflammatory Response; GO:0006954 inflammatory response; Reactome Neutrophil degranulation  
- **Interpretation:** This cluster contains macrophage-associated genes (`MERTK`, `STAB1`, `SPP1`, `CCL7`) and neutrophil-associated genes (`CD177`, `S100A12`, `SELL`, `MMP25`, `CXCR1`). Together they indicate innate immune activation, myeloid infiltration, and a profibrotic macrophage–neutrophil environment. MERTK is an efferocytosis receptor expressed by profibrotic macrophages; SPP1/osteopontin is a matricellular cytokine strongly linked to profibrotic macrophages in IPF.  
- **Strength / limitations:** Strong — many independent genes are highly significant, and the same biology has been repeatedly observed in IPF single-cell studies. However, bulk tissue expression may partly reflect the **number** of macrophages and neutrophils in the sample rather than activation per cell.

---

### Program 2 — Aberrant epithelial differentiation, mucinous metaplasia, and squamous metaplasia

- **Direction:** Higher expression → increased mortality  
- **Representative genes:** `MUC1` HR 2.32, `MUC21` HR 2.10, `CEACAM6` HR 2.66, `CEACAM7` HR 2.31, `KRT17` HR 2.19, `KRT23` HR 2.59, `SPRR1A` HR 2.28, `S100A14` HR 2.57, `GALNT14` HR 3.11, `SFTPB` HR 2.66, `SFTA2` HR 2.25, `SLC34A2` HR 2.27, `MAL2` HR 2.44, `AGR3` HR 2.40, `PKP3` HR 2.50  
- **Pathway anchor:** GO:0030855 epithelial cell differentiation; GO:0009913 mucin-type O-glycan biosynthetic process  
- **Interpretation:** These genes include mucins (`MUC1`, `MUC21`), cell-adhesion molecules of epithelial and neutrophil origin (`CEACAM6/7`), keratins and squamous differentiation markers (`KRT17`, `KRT23`, `SPRR1A`), alveolar epithelial markers (`SFTPB`, `SFTA2`, `SLC34A2`), and mucin-associated glycosylation enzymes (`GALNT14`). This pattern is best explained by **aberrant epithelial regeneration**, with alveolar type II cell hyperplasia, bronchiolar or mucinous metaplasia, and squamous metaplasia — all features of injured IPF lung.  
- **Strength / limitations:** Strong and biologically coherent. The main limitation is that some genes, especially CEACAM family members, are also expressed on neutrophils, so this program may partly overlap with the myeloid-inflammatory signal. It may also be a severity-associated consequence of advanced disease rather than a primary driver.

---

### Program 3 — Growth factor / receptor tyrosine kinase signaling and aberrant tissue repair

- **Direction:** Higher expression → increased mortality  
- **Representative genes:** `HGF` HR 2.93, `MET` HR 2.53, `NRG1` HR 2.76, `SPRY2` HR 3.26, `RGL1` HR 3.26, `MARCKS` HR 4.00  
- **Pathway anchor:** Reactome Signaling by Receptor Tyrosine Kinases; GO:0007169 transmembrane receptor protein tyrosine kinase signaling pathway  
- **Interpretation:** This cluster contains a direct ligand–receptor pair, HGF and MET, plus the growth factor NRG1 and the RTK-pathway feedback inhibitor SPRY2. SPRY2 is induced by RTK signaling and normally restrains Ras/MAPK activation; its higher expression implies that the pathway is actively engaged. This may reflect persistent epithelial/stromal injury-repair signaling. However, because HGF is classically viewed as regenerative and antifibrotic in experimental models, this signal must be interpreted cautiously.  
- **Strength / limitations:** Moderate — the presence of both ligand and receptor is compelling. The major limitation is a genuine conflict with published data suggesting HGF is protective in lung fibrosis; in this cohort, high HGF/MET may represent a failed or compensatory repair response, or correlate with disease severity rather than directly causing mortality.

---

### Program 4 — ECM remodeling and matricellular fibrosis program

- **Direction:** Higher expression → increased mortality  
- **Representative genes:** `HTRA1` HR 4.30, `EFEMP1` HR 2.33, `FBLIM1` HR 2.59, `FHL2` HR 2.76, `CHST15` HR 2.99, `HS3ST1` HR 3.24, `SUSD2` HR 2.31, `BMP6` HR 3.04; `SPP1` also overlaps here  
- **Pathway anchor:** GO:0030198 extracellular matrix organization; KEGG ECM-receptor interaction  
- **Interpretation:** These genes encode secreted proteases (HTRA1), extracellular matrix proteins or fibulins (EFEMP1), cell–matrix adaptors (FBLIM1, FHL2), glycosaminoglycan-sulfating enzymes (CHST15, HS3ST1), and matricellular proteins (SPP1). This indicates active matrix remodeling, altered growth factor bioavailability, and mechanosensitive cell–matrix signaling. HTRA1 is particularly interesting because it regulates TGF-β/BMP family signaling and extracellular matrix turnover.  
- **Strength / limitations:** Moderate to strong. The program is coherent but broad, and it overlaps with the myeloid and epithelial programs. Some genes may be expressed by fibroblasts, macrophages, or epithelial cells, and cell type cannot be resolved from this bulk tissue analysis.

---

### Program 5 — Oxidative stress, metal handling, and ferroptosis defense

- **Direction:** Higher expression → increased mortality  
- **Representative genes:** `SLC7A11` HR 3.52, `SLC39A8` HR 3.22, `STEAP4` HR 3.03, `SLC6A8` HR 3.21, `ACOX2` HR 3.18, `CYP4F3` HR 3.78, `SOD3` HR 2.37  
- **Pathway anchor:** KEGG Ferroptosis; Hallmark Reactive Oxygen Species Pathway  
- **Interpretation:** SLC7A11 encodes the cystine/glutamate antiporter, a central regulator of glutathione synthesis and ferroptosis resistance. STEAP4 is a metalloreductase involved in iron and copper handling; SLC39A8 is a zinc/iron transporter; SOD3 is an extracellular antioxidant enzyme; ACOX2 and CYP4F3 are lipid-metabolizing enzymes. Together these genes suggest that the IPF lung microenvironment is metabolically stressed and that cells are adapting to oxidative or ferroptotic stress.  
- **Strength / limitations:** Moderate and biologically distinct. The main limitation is cell-type ambiguity: SLC7A11 upregulation may protect epithelial cells from ferroptosis, but in fibroblasts it could represent resistance to ferroptosis and thereby promote fibrosis. These opposite possibilities cannot be separated from bulk tissue data.

---

## 3. Key genes and interaction modules

### 3.1 MERTK / SPP1 module — profibrotic macrophages

- **Direction:** Both risk-associated: MERTK HR = 3.70, SPP1 HR = 3.40  
- **Potential role:** MERTK mediates efferocytosis and is expressed by profibrotic macrophages; SPP1/osteopontin is a secreted matricellular cytokine involved in macrophage–fibroblast crosstalk.  
- **Gene–gene relationship:** Best described as **co-expression / pathway co-membership** in profibrotic macrophages. There is no evidence in this dataset of a direct physical interaction between MERTK and SPP1.

### 3.2 HGF / MET module — growth factor signaling

- **Direction:** Both risk-associated: HGF HR = 2.93, MET HR = 2.53  
- **Potential role:** HGF is the canonical ligand for MET. This is a genuine **direct ligand–receptor physical interaction**. High expression of both genes suggests active HGF/MET signaling, although whether this is protective/regenerative or maladaptive is unresolved.  
- **Related genes:** NRG1 and SPRY2 are also risk-associated and point to broader RTK signaling.

### 3.3 MUC1 / epithelial mucin / squamous metaplasia module

- **Direction:** Risk-associated: MUC1 HR = 2.32, MUC21 HR = 2.10, CEACAM6 HR = 2.66, CEACAM7 HR = 2.31, KRT17 HR = 2.19, SPRR1A HR = 2.28  
- **Potential role:** This module represents abnormal epithelial differentiation. MUC1 is clinically important because KL-6, a sialylated MUC1 glycoprotein, is an established serum biomarker in interstitial lung disease.  
- **Gene–gene relationship:** These genes are **co-expressed as part of a differentiation program**, not necessarily direct physical partners. Some CEACAM genes are also expressed by neutrophils, so the module may cross over into the myeloid-inflammatory program.

### 3.4 Neutrophil chemokine / alarmin module

- **Direction:** Risk-associated: CXCR1 HR = 3.28, CXCL1 HR = 2.99, S100A12 HR = 2.53, CD177 HR = 2.72, SELL HR = 2.37, MMP25 HR = 3.26, PROK2 HR = 3.65  
- **Potential role:** Neutrophil recruitment, activation, degranulation, and tissue injury.  
- **Gene–gene relationship:** **Co-expression / pathway co-membership**, not necessarily direct binding. Note that CXCL1 is a higher-affinity ligand for CXCR2 than CXCR1; S100A12 signals mainly through RAGE, not CXCR1. Therefore, calling this a direct CXCL1–CXCR1 interaction would be inaccurate.

### 3.5 SLC7A11 / ferroptosis-defense module

- **Direction:** Risk-associated: SLC7A11 HR = 3.52, SLC39A8 HR = 3.22, STEAP4 HR = 3.03, SOD3 HR = 2.37, ACOX2 HR = 3.18  
- **Potential role:** Protection from oxidative stress and ferroptosis; metal and lipid metabolic reprogramming.  
- **Gene–gene relationship:** **Pathway co-membership**, not direct protein interactions.

### 3.6 HTRA1 / ECM-remodeling module

- **Direction:** Risk-associated: HTRA1 HR = 4.30, EFEMP1 HR = 2.33, FBLIM1 HR = 2.59, CHST15 HR = 2.99, HS3ST1 HR = 3.24  
- **Potential role:** Matrix proteolysis, ECM sulfation, and altered TGF-β/BMP bioavailability.  
- **Gene–gene relationship:** **Pathway co-membership** in matrix remodeling; direct physical interactions are not established from the input data.

---

## 4. Validation priorities

| Priority | Category | Why prioritize | Current dataset evidence | External evidence | Most appropriate next step | Conclusion status |
|---|---|---|---|---|---|---|
| **Cell-composition confounding** | Confounding / composition check | Bulk lung tissue contains variable proportions of macrophages, neutrophils, epithelium, and fibroblasts; many risk genes are cell-lineage markers | MERTK, SPP1, STAB1, CD177, S100A12, SFTPB, SLC34A2, MUC1 are lineage-related | IPF lungs are histologically heterogeneous; single-cell studies show major changes in cell composition | Single-cell / single-nucleus RNA-seq, spatial transcriptomics, and deconvolution of bulk RNA with adjustment for estimated cell fractions in Cox models | Supported hypothesis |
| **MERTK / SPP1 profibrotic macrophage axis** | Mechanistic hypothesis | Strong HRs, biologically coherent, and linked to IPF macrophage biology | MERTK HR = 3.70; SPP1 HR = 3.40; STAB1 HR = 3.29 | SPP1-high profibrotic macrophages are described in IPF; MERTK marks efferocytic macrophages in fibrosis | Conditional Mertk deletion or anti-SPP1 antibody in bleomycin-induced pulmonary fibrosis; measure fibrotic burden and survival | Supported hypothesis |
| **SLC7A11 / ferroptosis resistance** | Therapeutic target | Multiple redox, metal, and ferroptosis-related genes are risk-associated; SLC7A11 is druggable and mechanistically testable | SLC7A11 HR = 3.52; SLC39A8, STEAP4, SOD3, ACOX2 also risk-associated | IPF fibroblasts may resist ferroptosis via SLC7A11; conflicting data also suggest alveolar epithelial ferroptosis contributes to fibrosis | Cell-type-specific SLC7A11 knockout in epithelial cells vs fibroblasts; assess ferroptosis markers and fibrosis in vivo | Exploratory hypothesis |
| **MUC1 / mucin-epithelial program as biomarker** | Biomarker | MUC1/KL-6 is already clinically used in ILD; tissue multi-gene mucin program may refine prognosis | MUC1 HR = 2.32; MUC21, CEACAM6/7, KRT17, SPRR1A risk-associated | KL-6/MUC1 is an established serum biomarker for interstitial lung disease prognosis | Measure tissue and plasma MUC1/mucin-related proteins in an independent IPF cohort; test association with mortality after adjusting for FVC, DLCO, GAP index, age, sex | Supported hypothesis for MUC1; exploratory for the multi-gene program |
| **HGF / MET signaling direction** | Interaction / network hypothesis | Both ligand and receptor are risk-associated, but HGF is classically anti-fibrotic in experimental models | HGF HR = 2.93; MET HR = 2.53; NRG1 and SPRY2 also risk | HGF is often protective in preclinical fibrosis models; MET is also an oncogene and can promote epithelial-mesenchymal programs | Spatial transcriptomics to identify HGF/MET-expressing cells; conditional Met deletion/activation in epithelial and mesenchymal cells in fibrosis models; test mortality endpoints | Exploratory hypothesis — the conflict with existing anti-fibrotic HGF literature must be resolved |

---

## 5. Evidence grounding

The interpretation is supported by several evidence categories, but they differ in independence:

- **Input dataset:** All genes in the biological programs have highly significant HRs and FDRs. This is direct prognostic evidence within this IPF cohort.
- **Pathway / ontology evidence:** Program assignments are based on curated gene annotations. This helps organize the biology but is **not independent** of the input gene list; it is an interpretive layer.
- **Protein interaction / regulatory evidence:** The strongest direct interaction is HGF–MET, a ligand–receptor pair. Other relationships are largely co-expression or pathway co-membership.
- **Disease-association evidence:** MERTK/SPP1 profibrotic macrophages and MUC1/KL-6 are well supported in IPF literature. However, these literature associations may share underlying data sources with each other and should not be treated as fully independent from expression-based evidence.
- **Expression / tissue-specific evidence:** The data are from bulk lung tissue; cell-type specificity is unknown.
- **Genetic / clinical evidence:** No GWAS, Mendelian randomization, or clinical covariate-adjusted model was provided. The main clinical anchor is the established MUC1/KL-6 biomarker literature.
- **Drug / therapeutic evidence:** The availability of drugs against some genes does not constitute evidence of efficacy in IPF. This is especially relevant for SLC7A11/ferroptosis and MERTK: inhibition may be beneficial or harmful depending on cell type and disease stage.

Overall, the strongest integrated evidence supports:

- A risk-associated **myeloid-inflammatory / profibrotic macrophage** program;
- A risk-associated **mucinous/squamous epithelial metaplasia** program;
- A **biomarker rationale** centered on MUC1;
- An **exploratory but mechanistically plausible** oxidative stress / ferroptosis-defense axis;
- An **uncertain direction** for HGF/MET signaling.

---

## 6. Limitations and alternative explanations

### 6.1 Bulk tissue cell composition

Many risk-associated genes are lineage markers. In bulk IPF lung tissue, increased expression of `MERTK`, `SPP1`, `CD177`, or `SFTPB` may simply indicate more macrophages, neutrophils, or type II alveolar epithelial cells, not increased expression per cell. This could be addressed by single-cell RNA-seq, spatial transcriptomics, multiplex immunohistochemistry, or computational deconvolution with adjustment for cell fractions in survival models.

### 6.2 Disease severity and clinical confounding

All-cause mortality in IPF is strongly influenced by age, sex, baseline FVC, DLCO, and disease extent. The supplied results are univariate or at least not shown to be adjusted for these factors. Therefore, many genes may be **severity markers** rather than independent prognostic factors. Validation in a multivariate Cox model with clinical variables is essential.

### 6.3 Treatment and tissue sampling timing

IPF patients may be treated with corticosteroids, immunosuppressants, pirfenidone, or nintedanib before tissue sampling. These treatments can alter inflammatory, epithelial, and fibrotic gene expression. The timing and type of tissue sample also matter: surgical lung biopsy, transbronchial biopsy, and explanted lung at transplant represent different disease stages. These factors could strongly influence the observed hazard ratios.

### 6.4 Statistical artifacts and unannotated features

Several features with extreme HRs and P = 0 should not be interpreted biologically. The presence of control probes, uncharacterized `XLOC`/`lincRNA` features, and reciprocal extreme HRs strongly suggests non-identifiable Cox fits or platform artifacts. In a final analysis, these features should be filtered using expression prevalence and penalized/Firth Cox regression. `LOC100128226` is the only finite protective signal, but its unknown annotation means the evidence is insufficient to support a protective program.

### 6.5 Broad pathway overlap and association-versus-causation ambiguity

The five programs overlap biologically. For example, SPP1 belongs to both the myeloid-inflammatory and ECM programs; CEACAM genes are on both epithelial and neutrophil surfaces; many genes are downstream of shared transcription factors such as NF-κB, STAT3, or HIF-1α. Therefore, the apparent “programs” are not fully independent. Additionally, all associations are correlational. The conflicting HGF/MET literature illustrates that a risk-associated HR does not prove that the gene is driving mortality; it may reflect a failed regenerative response or disease severity.

---

## Final conclusion

In this IPF prognostic transcriptome, the credible signal is overwhelmingly risk-associated and reflects a coordinated biology of **myeloid inflammation, aberrant epithelial metaplasia, growth factor / RTK signaling, ECM remodeling, and oxidative-stress adaptation**. The only significant protective gene is unannotated, so no protective biological program can be proposed. These findings are useful for prioritizing mechanistic experiments and biomarker validation, but they should not be interpreted as causal evidence or as proof that any individual gene is an effective therapeutic target in IPF.
